Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular (Wet) Age-Related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT04268836
What this trial is testing

Vision Improvement for Patients With Age-Related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Optimal Acuity Corporation 200
Large-scale testing (Phase 3)Study completedNCT01436864
What this trial is testing

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Chengdu Kanghong Biotech Co., Ltd. 125
Large-scale testing (Phase 3)Study completedNCT03034772
What this trial is testing

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular Degeneration
Wills Eye 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07557121
What this trial is testing

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
AiViva BioPharma, Inc. 35
Not applicableStudy completedNCT05082415
What this trial is testing

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 9,456
Testing effectiveness (Phase 2)Study completedNCT04626128
What this trial is testing

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Clearside Biomedical, Inc. 27
Large-scale testing (Phase 3)Study completedNCT04964089
What this trial is testing

Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Who this might be right for
Wet Age-related Macular Degeneration
Kodiak Sciences Inc 557
Not applicableStudy completedNCT05110209
What this trial is testing

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 331,541
Large-scale testing (Phase 3)Ended earlyNCT04757636
What this trial is testing

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 998
Post-approval studies (Phase 4)Study completedNCT02305238
What this trial is testing

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Macular Degeneration
Bayer 288
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Not applicableStudy completedNCT05324150
What this trial is testing

M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD

Who this might be right for
Macular Degeneration, WetMetamorphopsia
Ospedale Santa Croce-Carle Cuneo 57
Testing effectiveness (Phase 2)Study completedNCT01134055
What this trial is testing

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
GlaxoSmithKline 510
Large-scale testing (Phase 3)Study completedNCT04857177
What this trial is testing

Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Who this might be right for
Neovascular(Wet) Age Related Macular Degeneration
Chong Kun Dang Pharmaceutical 312
Not applicableActive Not RecruitingNCT06717139
What this trial is testing

Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD

Who this might be right for
Retinal DiseasesMacular DegenerationNeovascular (Wet) Age-Related Macular Degeneration
St. Erik Eye Hospital 220
Large-scale testing (Phase 3)Looking for participantsNCT07064759
What this trial is testing

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics 480
Testing effectiveness (Phase 2)Study completedNCT03345082
What this trial is testing

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 366
Large-scale testing (Phase 3)Study completedNCT00891735
What this trial is testing

Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

Who this might be right for
Age-related Macular Degeneration
Genentech, Inc. 1,097
Very early researchNot Yet RecruitingNCT06888492
What this trial is testing

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

Who this might be right for
Wet Age-related Macular Degeneration (wAMD)Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 8
Post-approval studies (Phase 4)Study completedNCT02581891
What this trial is testing

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Who this might be right for
Macular Degeneration
Bayer 287
Next Page